Synergistic nano-drug for removing fibrosis and inhibiting pancreatic cancer metastasis and preparation method of nano-drug
By designing nanomedicines through the self-assembly of small molecule prodrugs and hybrid membrane coating, the problems of low drug loading rate and non-responsive release in the treatment of pancreatic cancer have been solved, achieving efficient defibrosis and metastasis inhibition, and providing a new treatment approach for pancreatic cancer.
Patent Information
- Application Number
- CN202411075368.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-22
AI Technical Summary
Existing nanomedicines suffer from problems such as low drug loading rate, non-responsive release, single signaling pathway regulation, and difficulty in synergistic effects in defibrosis and inhibiting pancreatic cancer metastasis, resulting in unsatisfactory therapeutic effects.
Nanoparticles are formed by the self-assembly of the small molecule prodrug Cap-tkCA-Cap and coated with activated macrophage/fibroblast hybrid cell membranes to achieve homologous targeting and receptor protein-mediated targeting of pancreatic cancer fibrotic adhesion stroma. Cap and CA are rapidly released through ROS response, synergistically inhibiting the TGF-β/Smad and PI3K/AKT signaling pathways.
It achieves high drug loading rate, rapid responsive drug release, synergistic defibrosis and inhibition of pancreatic cancer cell metastasis, and significant dynamic synergistic therapeutic effect.
Smart Images

Figure CN118986918A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical preparations, in particular to a nano drug for synergistically defibrosis and inhibition of pancreatic cancer metastasis and a preparation method thereof. Background Art
[0002] Dense fibrotic adhesion stroma is one of the main reasons for the failure of pancreatic cancer treatment. As a typical histopathological feature of pancreatic cancer, it is a natural protective physical barrier for pancreatic cancer, which can block the effective delivery of chemotherapeutic drugs and protect cancer cells from the effects of conventional chemotherapeutic drugs, thereby leading to the generation of chemotherapeutic resistance. Any effective chemotherapy must overcome the obstacles of fibrotic adhesion stroma, so how to efficiently resolve fibrosis has always been a bottleneck problem in the treatment of pancreatic cancer. On the other hand, due to the strong invasiveness of pancreatic cancer cells, resolution of fibrosis will increase the risk of pancreatic cancer metastasis. Therefore, how to effectively inhibit the metastasis of pancreatic cancer cells while efficiently resolving fibrosis has become another difficult problem in the treatment of pancreatic cancer. Therefore, it is of great significance to construct a drug delivery system that can both efficiently resolve fibrosis and effectively inhibit the metastasis of cancer cells for the treatment of pancreatic cancer.
[0003] Nanomedicine has opened up a new path to improve the therapeutic effect of cancer. Compared with small molecule drugs, nanomedicine has many advantages, such as longer blood circulation time in the body, more efficient enrichment at the tumor site, and functionalized nanomedicine can specifically release drugs in the tumor microenvironment. It can be seen that nanomedicine can effectively improve the targeting and bioavailability of drugs, thereby reducing the side effects of treatment. At present, nanomedicine mainly relies on excipients such as liposomes or polymers to form nanoparticles. Since excipients occupy most of the mass of nanomedicines, the drug loading of nanomedicines is usually very low, and the therapeutic effect is often unsatisfactory because the effective drug concentration cannot be reached. If the dosage is increased, it is difficult to avoid the systemic toxicity caused by the excipient. Nanomedicine based on small molecule self-assembly just perfectly solves the above problems. The absence of excipients makes it have a high drug loading rate, which minimizes the toxic and side effects caused by excipients, has more reliable safety in treatment, and the preparation method of small molecule self-assembly nanomedicines is often simpler and more environmentally friendly.
[0004] In recent years, in order to improve the treatment efficiency of pancreatic tumors, researchers have developed various nano-drug delivery systems to regulate the fibrotic adhesion stroma of pancreatic cancer. The strategies mainly include: (1) using polymers or liposomes as carriers to deliver TGF-β / Smad signaling pathway inhibitors (such as ash, metformin, and α-mangostin) to inhibit the activation pathway of pancreatic stellate cells and reduce the generation of cancer-related fibroblasts, thereby reducing the formation of fibrotic adhesion stroma; (2) using liposomes or inorganic nanoparticles as carriers to deliver pancreatic stellate cell activity inhibitors (pirfenidone, all-trans retinoic acid) to inhibit the activity of pancreatic stellate cells and slow down the formation of fibrotic adhesion stroma; (3) using liposomes as carriers to deliver photothermal therapeutic agents to ablate the fibrotic adhesion stroma of pancreatic cancer through photothermal action. The above-mentioned research on defibrotization has greatly promoted the application of defibrotization nanomedicines, but there are also many shortcomings: first, it is difficult to achieve defibrotization and metastasis inhibition at the same time; second, with the help of specific carriers, the drug is only loaded by simple encapsulation or adsorption, the drug loading rate is low, it is difficult to achieve responsive release, and the selectivity is poor; third, the signal pathway regulation is relatively single, it is difficult to form a synergistic effect, and the defibrotization efficiency is low. Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides a nano drug that synergistically resolves fibrosis and inhibits pancreatic cancer metastasis and a preparation method thereof.
[0006] To achieve the above object, the present invention is implemented according to the following technical solutions:
[0007] One of the purposes of the present invention is to provide a method for preparing a nano drug that can synergistically resolve fibrosis and inhibit pancreatic cancer metastasis, comprising the following steps:
[0008] S1. Trifluoroacetic acid, captopril Cap and cinnamaldehyde CA in a molar ratio of 1:1:1 are mixed. Under the catalytic action of trifluoroacetic acid, the thiol group of captopril Cap and the aldehyde group of cinnamaldehyde CA undergo a condensation reaction. Captopril Cap and cinnamaldehyde CA are connected through a ROS-sensitive tk bond to obtain a small molecule prodrug Cap-tkCA-Cap; and the small molecule prodrug Cap-tkCA-Cap is treated to obtain small molecule prodrug nanoparticles Cap-tkCA-Cap NPs;
[0009] S2. Preparation of activated macrophage / fibroblast hybrid cell membranes;
[0010] S3. The activated macrophage / fibroblast hybrid cell membrane was used to coat the small molecule prodrug nanoparticles Cap-tkCA-CapNPs to obtain the nanodrug Cap-tkCA-Cap@CM.
[0011] Furthermore, in step S1, the small molecule prodrug Cap-tkCA-Cap is processed specifically as follows:
[0012] The small molecule prodrug Cap-tkCA-Cap was dissolved in dimethyl sulfoxide (DMSO) to obtain a mixed solution, which was slowly dripped into deionized water under ultrasound, and was dialyzed and purified using a dialysis bag with a molecular weight cutoff of 1000Da to obtain small molecule prodrug nanoparticles Cap-tkCA-CapNPs.
[0013] Specifically, the step S2 includes:
[0014] S21, macrophage RAW264.7 were incubated with 10 ng / mL LPS, and then activated macrophage membranes were extracted by ultrasound and centrifugation;
[0015] S22, normal fibroblasts NIH3T3 were incubated with 10 ng / mL TGF-β1, and then activated fibroblast membranes were obtained by ultrasonic and centrifugal extraction;
[0016] S23. The activated macrophage membrane and the activated fibroblast membrane are mixed by ultrasound at a mass ratio of 1:1, and the membrane fusion is promoted by repeated extrusion through a polycarbonate porous membrane to obtain an activated macrophage / fibroblast hybrid cell membrane.
[0017] Specifically, step S3 includes:
[0018] 1 mg / mL small molecule prodrug nanoparticles Cap-tkCA-Cap NPs were mixed with a hybrid membrane of 5 million activated macrophages and 5 million fibroblasts and then sonicated, and then extruded through a polycarbonate porous membrane to obtain the nanodrug Cap-tkCA-Cap@CM.
[0019] Preferably, the pore size of the polycarbonate porous membrane is 100-400 nm.
[0020] The second purpose of the present invention is to provide a nano drug prepared by the above method that synergistically resolves fibrosis and inhibits pancreatic cancer metastasis.
[0021] The mechanism of the nano drug Cap-tkCA-Cap@CM prepared by the present invention is:
[0022] During delivery, the hybrid membrane provides nanodrugs with long in vivo circulation, homologously targets fibroblasts in the fibrotic adhesion stroma of pancreatic cancer, and simultaneously targets HA and fibronectin in the stroma through receptor protein-mediated targeting, and efficiently accumulates in the fibrotic adhesion stroma. In the fibrotic adhesion stroma of pancreatic cancer, high levels of ROS cleave the tk bond of Cap-tkCA-Cap, releasing Cap and CA rapidly, in large quantities, and without leaving any traces; Cap and CA respectively inhibit the TGF-β / Smad signaling pathway, reduce the secretion of ECM proteins, inhibit the formation of fibrotic adhesion stroma, and synergistically resolve fibrosis. As the fibrosis resolves, the bionic nanodrugs further respond rapidly to release in pancreatic cancer cells, and Cap and CA respectively reduce the invasiveness of pancreatic cancer cells by inhibiting the TGF-β / Smad and PI3K / AKT signaling pathways, and synergistically inhibit the occurrence of metastasis.
[0023] Compared with the prior art, the present invention achieves no excipient-related toxicity and high drug loading rate through the self-assembly of small molecule prodrugs, realizes homologous targeting of fibrotic adhesion stroma and receptor protein-mediated active targeting through the coating of hybrid membranes, realizes large-scale, rapid and traceless drug release in fibrotic adhesion stroma through the response of prodrug molecules to ROS, and eliminates the self-limiting characteristics of responsive small molecule drug release; the released drugs Cap and CA can simultaneously inhibit fibrosis signals / proteins and synergistically resolve fibrosis; as the resolution of fibrosis proceeds, the Cap and CA released rapidly and tracelessly in pancreatic cancer cells can simultaneously inhibit the metastasis / invasion signal pathways of pancreatic cancer cells and synergistically inhibit the occurrence of metastasis; the process of resolution of fibrosis and the process of inhibiting metastasis dynamically cooperate, providing a new way for the resolution of fibrosis in the treatment of pancreatic cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is a diagram of the preparation process of the nanomedicine of the present invention that synergistically resolves fibrosis and inhibits pancreatic cancer metastasis.
[0025] Figure 2 The structure of the small molecule prodrug Cap-tkCA-Cap was determined by H NMR spectroscopy ( 1 1H NMR).
[0026] Figure 3 The structure of the small molecule prodrug Cap-tkCA-Cap was determined by carbon NMR spectroscopy ( 13 C NMR)
[0027] Figure 4 This is the high-resolution mass spectrum HR-MS graph of the small molecule prodrug Cap-tkCA-Cap.
[0028] Figure 5The graph shows the particle size changes of the pro-small molecule prodrug nanoparticles Cap-tkCA-Cap NPs and nanodrug Cap-tkCA-Cap@CM.
[0029] Figure 6 This is the surface charge value diagram of the nanodrug Cap-tkCA-Cap@CM.
[0030] Figure 7 Transmission electron microscopy TEM images of Cap-tkCA-Cap NPs and Cap-tkCA-Cap@CM.
[0031] Figure 8 High-resolution mass spectrometry HR-MS graph of the drug release of Cap and CA in response to reactive oxygen species (ROS) in the simulated physiological environment of the nanodrug Cap-tkCA-Cap@CM.
[0032] Fig. 9 High performance liquid chromatography drug release profile of Cap and CA of the nanodrug Cap-tkCA-Cap@CM in response to reactive oxygen species (ROS) in a simulated physiological environment.
[0033] Fig.10 These are the evaluation results of the defibrotogenic ability of Cap-tkCA-Cap@CM, blank group, Cap, and CA group.
[0034] Fig.11 The expression of α-SMA, Fibronectin, and ColI in NIH3T3 cells treated with different concentrations of Cap-tkCA-Cap@CM.
[0035] Fig.12 The results of inhibiting pancreatic cancer cell metastasis without or with Cap-tkCA-Cap@CM.
[0036] Fig.13 The results of inhibition of pancreatic cancer cell invasion without or with Cap-tkCA-Cap@CM.
[0037] Fig.14 The results of inhibiting pancreatic cancer metastasis in mice without Cap-tkCA-Cap@CM and with the addition of nanodrug Cap-tkCA-Cap@CM.
[0038] Fig.15 This is the application effect of nanodrug Cap-tkCA-Cap@CM in the treatment of pancreatic cancer in mice. DETAILED DESCRIPTION
[0039] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not used to limit the invention.
[0040] Unless otherwise specified, the raw materials, reagents, equipment and tools used in the following examples were commercially available.
[0041] Captopril (Cap) was purchased from Sigma-Aldrich;
[0042] Cinnamaldehyde (CA) was purchased from Sigma-Aldrich;
[0043] Macrophage RAW 264.7 was purchased from Wuhan Pronocell Life Science Technology Co., Ltd.;
[0044] Normal fibroblasts NIH3T3 were purchased from Wuhan Pronocell Life Science Technology Co., Ltd.;
[0045] TGF-β1 was purchased from Sigma-Aldrich.
[0046] Example 1. Preparation of nanomedicine that synergistically resolves fibrosis and inhibits pancreatic cancer metastasis
[0047] like Figure 1 As shown, this embodiment exemplarily demonstrates a method for preparing a nano drug that synergistically resolves fibrosis and inhibits pancreatic cancer metastasis, and the specific steps are as follows:
[0048] S1. Trifluoroacetic acid, captopril Cap and cinnamaldehyde CA in a molar ratio of 1:1:1 are mixed. Under the catalytic action of trifluoroacetic acid, the thiol group of captopril Cap and the aldehyde group of cinnamaldehyde CA undergo a condensation reaction. Captopril Cap and cinnamaldehyde CA are connected through a ROS-sensitive tk bond to obtain a small molecule prodrug Cap-tkCA-Cap; and the small molecule prodrug Cap-tkCA-Cap is treated to obtain small molecule prodrug nanoparticles Cap-tkCA-Cap NPs. The reaction formula is as follows:
[0049]
[0050] The structure of the small molecule prodrug Cap-tkCA-Cap was determined by hydrogen and carbon nuclear magnetic resonance spectra (1HNMR, 13CNMR) (see Figure 2 , Figure 3 ) and high resolution mass spectrometry (HR-MS) ( Figure 4 ) was characterized; and its structure was finally determined to be the structure in the above reaction formula.
[0051] Then the small molecule prodrug Cap-tkCA-Cap was dissolved in dimethyl sulfoxide (DMSO) to obtain a mixed solution, and the mixed solution was slowly dripped into deionized water under ultrasound, and dialyzed and purified using a dialysis bag with a molecular weight cutoff of 1000Da to obtain small molecule prodrug nanoparticles Cap-tkCA-Cap NPs.
[0052] S2. Preparation of activated macrophage / fibroblast hybrid cell membranes;
[0053] S21, macrophage RAW264.7 were incubated with 10 ng / mL LPS at 37°C for 12 hours, and the activated cell membrane surface integrin protein content was characterized by Western blotting (WB), the protein ligands were vascular adhesion factor and fibrous tissue adhesion protein; then the activated macrophage membrane was extracted by ultrasound (500 W, 20 kHz, 5 min) and centrifugation (30 min, 4°C, 14000 g);
[0054] S22, normal fibroblasts NIH3T3 were incubated with 10 ng / mL TGF-β1 at 37°C for 12 h, and then activated fibroblast membranes were extracted by ultrasound (500 W, 20 kHz, 5 min) and centrifugation (30 min, 4°C, 14000 g);
[0055] S23. The activated macrophage membrane and the activated fibroblast membrane were mixed by ultrasound at a mass ratio of 1:1 (500 W, 20 kHz, 5 min), and the membrane fusion was promoted by repeated extrusion through a polycarbonate porous membrane to obtain an activated macrophage / fibroblast hybrid cell membrane.
[0056] S3. 1 mg / mL of small molecule prodrug nanoparticles Cap-tkCA-Cap NPs were mixed with a hybrid membrane of 5 million activated macrophages and 5 million fibroblasts, and then ultrasonicated (500 watts, 20 kHz, 5 minutes), and extruded through a polycarbonate porous membrane to obtain nanodrug Cap-tkCA-Cap@CM. The coating of the hybrid membrane was determined by gel electrophoresis, and the hydrated particle size and surface charge value of the small molecule prodrug nanoparticles Cap-tkCA-Cap NPs and nanodrug Cap-tkCA-Cap@CM were determined by dynamic light scattering (DLS) and Zeta potential analyzer. DLS was used to characterize their particle size changes at different times. The results are shown in Figure 5 , Figure 6 As shown by Figure 5 , Figure 6It can be seen that small molecule prodrugs can self-assemble into nanoparticles, and the nanodrug Cap-tkCA-Cap@CM coated with cell membrane has good stability. Transmission electron microscopy (TEM) was used to observe their morphological characteristics. The TEM morphology of Cap-tkCA-Cap NPs and Cap-tkCA-Cap@CM is shown in Figure 2. Figure 7 As shown by Figure 7 It can be seen that the cell membrane is successfully coated on the surface of the nanoparticles.
[0057] Example 2. Drug release behavior of nanomedicine Cap-tkCA-Cap@CM in response to reactive oxygen species (ROS) in a simulated physiological environment
[0058] In buffer solution, Cap-tkCA-Cap@CM reacted with ROS (5 mM H 2 O 2 ) were used to characterize the drug release behaviors of Cap and CA by HR-MS and high performance liquid chromatography (HPLC), and the drug release kinetics data of nanodrug Cap-tkCA-Cap@CM were obtained. First, Cap-tkCA-Cap@CM was dispersed in PBS at a concentration of 5 mg / mL, and then H 2 O 2 , so that H 2 O 2 The concentration was 5 mM, and then stirred at room temperature. HR-MS tests were performed at 5 minutes, 15 minutes, and 30 minutes. The results were as follows Figure 8 As shown in the figure, with the increase of time, the mass spectrometry peak intensity of Cap-tkCA-Cap gradually decreased, while the peak intensity of Cap and CA gradually increased, which fully proved that the nanodrug Cap-tkCA-Cap@CM released Cap and CA rapidly and tracelessly under the action of ROS. Secondly, Cap-tkCA-Cap@CM was dispersed in PBS at a concentration of 5 mg / mL, and then H 2 O 2 (5 mM), samples were taken at different time points for HPLC testing (absorption wavelength of 220 nm to monitor the release of Cap, and absorption wavelength of 291 nm to monitor the release of CA), and the results are shown in Fig. 9 As shown, Cap-tkCA-Cap@CM has no H 2 O 2 In the case of , the release of Cap and CA is basically negligible, while when H 2 O 2After addition, the release rates of Cap and CA exceeded 70% within 10 min, and reached nearly 95% at 30 min, which further demonstrated that the nanomedicine Cap-tkCA-Cap@CM has the performance of rapid response to ROS and release of Cap and CA.
[0059] Example 3: Study on the defibrosis and inhibition of metastasis and invasion of nanomedicine Cap-tkCA-Cap@CM
[0060] (1) Evaluation of the defibrillation ability of Cap-tkCA-Cap@CM
[0061] The anti-fibrotic ability of bionic nanomedicines was investigated by cell immunofluorescence staining: NIH3T3 cells (denoted as control group) were activated by incubation with 10 ng / mL TGF-β1 at 37°C for 24 h (denoted as TGF-β group), and then activated by 10 μg / mL Cap (denoted as TGF-βCap group), 10 μg / mL CA (denoted as TGF-βCA group), 5 μg / mL Cap-tkCA-Cap@CM (denoted as TGF-βCap-tkCA-Cap@CM 5 μg / mL group) and 10 μg / mL Cap-tkCA-Cap@CM (denoted as TGF-βCap-tkCA-Cap@CM 5 μg / mL group). The cells were incubated at 37°C for 24 hours, fixed with 4% formaldehyde for 15 minutes, and then incubated with α-SMA, fibronectin primary antibody, and fluorescein-labeled secondary antibody. After the culture medium was removed, the cells were washed three times with PBS, and incubated with cell core dye DAPI for 15 minutes for fluorescence imaging. The results are shown in Figure 2. Fig.10 As shown in the figure, after activation by TGF-β1, fibrosis-related proteins α-SMA and Fibronectin were expressed in large quantities. After treatment with Cap or CA, the fibrosis proteins of cells decreased to a certain extent. When treated with 5μg / mL Cap-tkCA-Cap@CM, cell fibrosis was significantly reduced. When the concentration of Cap-tkCA-Cap@CM was 10μg / mL, the expression of α-SMA and Fibronectin was basically not observed in the cells, which proved that Cap-tkCA-Cap@CM has significant anti-fibrosis ability.
[0062] In addition, the expression of α-SMA, Fibronectin, and Col I in NIH3T3 treated with different concentrations of Cap-tkCA-Cap@CM (0.1μg / mL, 1μg / mL, 5μg / mL, 10μg / mL) was investigated by western blotting (WB): the cells treated with nanomedicine were lysed and proteins were extracted from the cells. The proteins of each sample were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the proteins were transferred to polyvinylidene fluoride (PVDF) membranes. After the membranes were treated with T-TBS buffer containing 5% skim milk for 1 hour, they were incubated with primary antibodies for GAPDH (1:1000), α-SMA (1:5000), ColⅠ (1:1000) and Fibronectin (1:1000) at 4°C overnight, and then incubated with secondary antibodies for 1 hour. Finally, the membranes were washed and imaged using a chemiluminescence detection kit. The results are shown in Figure 2. Fig.11 As shown, from Fig.11 It can be observed that with the increase of Cap-tkCA-Cap@CM concentration, the expression levels of fibrotic proteins α-SMA, Fibronectin and Col I continued to decrease. This further proves that the nanodrug Cap-tkCA-Cap@CM has outstanding anti-fibrotic ability.
[0063] (2) Investigation of the ability of Cap-tkCA-Cap@CM to inhibit metastasis and invasion of pancreatic cancer cells
[0064] The ability of bionic nanomedicine to inhibit pancreatic cancer cell metastasis and invasion was evaluated by cell scratch test and Transwell invasion assay.
[0065] Cell scratch test: After pancreatic cancer cells (PANC-1) grew into a fully confluent monolayer, a linear scratch was made on the cell monolayer with a sterile pipette tip. The cells were cultured with a medium containing Cap-tkCA-Cap@CM (10 μg / mL). The control group without the addition of nanomedicine was used as the control group. After 48 hours, the migration distance of the cells was observed and imaged. The results are shown in Figure 2. Fig.12 As shown. Fig.12 It can be found that the cells without Cap-tkCA-Cap@CM have basically fused at the scratch, while the cells incubated with nanodrug Cap-tkCA-Cap@CM have basically no cell growth. This shows that nanodrug Cap-tkCA-Cap@CM can effectively inhibit the metastasis and invasion of PANC-1 cells.
[0066] Transwell invasion assay: A small chamber with matrix gel (8 μm) was used. PANC-1 cells were added to the upper chamber, and serum-free culture medium containing Cap-tkCA-Cap@CM (10 μg / mL) was added. Complete culture medium containing 10% FBS was added to the lower chamber. After incubation at 37°C for 24 hours, the non-infiltrated cells on the upper surface of the membrane were wiped off, the infiltrated cells were fixed, stained with crystal violet, and randomly selected areas were imaged under a microscope. The results are shown in Figure 2. Fig.13 As shown. Fig.13 It can be found that when the nanodrug Cap-tkCA-Cap@CM is not treated, PANC-1 cells quickly migrate and invade, while in the components treated with the nanodrug Cap-tkCA-Cap@CM, very few PANC-1 cells can be observed, indicating that the nanodrug Cap-tkCA-Cap@CM has a significant inhibitory effect on the migration and invasion of PANC-1 cells.
[0067] Example 4: Application of Nanodrug Cap-tkCA-Cap@CM in Inhibiting Pancreatic Cancer Metastasis in Living Body and in Treating Pancreatic Cancer
[0068] (1) Study on the inhibition of pancreatic cancer metastasis by nanodrug Cap-tkCA-Cap@CM
[0069] Source of mice: Hangzhou Paisiao Biotechnology Co., Ltd.; Breed: BALB / c mice, 20-25g.
[0070] BALB / c mice aged 6-8 weeks were selected and pancreatic cancer cells PANC-1-luci (1×10 6 ) and NIH3T3 cells (1×10 6 ) was mixed with matrix gel and injected into mice through the tail vein. One day later, mice were given medication through the tail vein (Cap-tkCA-Cap@CM dosage was 10 mg / kg, once every two days, for a total of 5 times). D-luciferin potassium salt (200 μL, 10 mg / mL) was injected 10 minutes before imaging. Bioluminescence imaging was performed on the mice to observe the metastasis of the tumor. The mice injected with PBS were used as the control group. The results are shown in Fig.14 As shown. Fig.14 It can be seen that the lungs of mice in the PBS group glowed strongly, indicating that pancreatic cancer cells metastasized to the lungs in large numbers. In sharp contrast to the PBS group, mice in the nanodrug Cap-tkCA-Cap@CM group only showed extremely weak light, which proved that the nanodrug Cap-tkCA-Cap@CM can effectively inhibit the metastasis and invasion of pancreatic cancer cells in mice.
[0071] (3) Application of nanomedicine Cap-tkCA-Cap@CM in the treatment of pancreatic cancer
[0072] Based on the above pancreatic cancer fibrosis and metastasis inhibition, this nano drug is combined with gemcitabine (GEM), a first-line chemotherapy drug for pancreatic cancer, to explore the application of this nano drug in the treatment of pancreatic cancer. PANC-1 (1×10 6 ) and NIH3T3 cells (1×10 6 ) was mixed with matrix gel and inoculated into the subcutaneous tissue of the right forelimb of BALB / c nude mice to construct a subcutaneous transplant tumor model. One week later, the mice were randomly divided into groups (PBS group, GEM group, Cap-tkCA-Cap@CM group, Cap-tkCA-Cap@CM+GEM group). PBS group (intravenous injection of 200 μL PBS, once every 2 days from day 0 to day 12); GEM group (intravenous injection, 15 mg / kg, once every 2 days from day 6 to day 12); Cap-tkCA-Cap@CM group (intravenous injection, 10 mg / kg, once every 2 days from day 0 to day 12); Cap-tkCA-Cap@CM+GEM group: Cap-tkCA-Cap@CM intravenous injection, 10 mg / kg, once every 2 days from day 0 to day 12, GEM intravenous injection, 15 mg / kg, once every 2 days from day 6 to day 12). The tumor volume was recorded every two days until the 24th day to investigate the effect of nanomedicine in the treatment of pancreatic cancer in mice. Fig.15 As shown, Cap-tkCA-Cap@CM was first administered to tumor-bearing mice to resolve fibrosis, and then GEM was administered for treatment. It was found that the tumors of the mice were well inhibited, indicating that the nanodrug Cap-tkCA-Cap@CM has a good effect in the treatment of pancreatic cancer.
[0073] In summary, the present invention achieves no excipient-related toxicity and high drug loading rate through small molecule prodrug self-assembly, realizes homologous targeting of fibrotic adhesion stroma and receptor protein-mediated active targeting through hybrid membrane coating, and realizes large-scale, rapid and traceless drug release in fibrotic adhesion stroma through the response of prodrug molecules to ROS, thereby eliminating the self-limiting characteristics of responsive small molecule drug release; the released drugs Cap and CA can simultaneously inhibit fibrosis signaling proteins and synergistically resolve fibrosis; as the resolution of fibrosis proceeds, the Cap and CA released rapidly and tracelessly in pancreatic cancer cells can simultaneously inhibit the metastasis and invasion of pancreatic cancer cells and synergistically inhibit the occurrence of metastasis; the process of resolution of fibrosis and the process of inhibiting metastasis dynamically cooperate, providing a new way for the resolution of fibrosis in the treatment of pancreatic cancer.
[0074] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. All technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.
Claims
1. A method for preparing a nano drug that synergistically resolves fibrosis and inhibits pancreatic cancer metastasis, characterized in that: The following steps are involved: S1. Trifluoroacetic acid, captopril Cap and cinnamaldehyde CA in a molar ratio of 1:1:1 are mixed. Under the catalytic action of trifluoroacetic acid, the thiol group of captopril Cap and the aldehyde group of cinnamaldehyde CA undergo a condensation reaction. Captopril Cap and cinnamaldehyde CA are connected through a ROS-sensitive tk bond to obtain a small molecule prodrug Cap-tkCA-Cap; and the small molecule prodrug Cap-tkCA-Cap is treated to obtain small molecule prodrug nanoparticles Cap-tkCA-Cap NPs; S2. Preparation of activated macrophage / fibroblast hybrid cell membranes; S3. The activated macrophage / fibroblast hybrid cell membrane was used to coat the small molecule prodrug nanoparticles Cap-tkCA-CapNPs to obtain the nanodrug Cap-tkCA-Cap@CM.
2. The method for preparing the nanomedicine for synergistically defibrosis and inhibiting pancreatic cancer metastasis according to claim 1, characterized in that: In step S1, the small molecule prodrug Cap-tkCA-Cap is processed specifically as follows: The small molecule prodrug Cap-tkCA-Cap was dissolved in dimethyl sulfoxide (DMSO) to obtain a mixed solution, which was slowly dripped into deionized water under ultrasound, and was dialyzed and purified using a dialysis bag with a molecular weight cutoff of 1000Da to obtain small molecule prodrug nanoparticles Cap-tkCA-CapNPs.
3. The method for preparing the nanomedicine for synergistically defibrosis and inhibiting pancreatic cancer metastasis according to claim 1, characterized in that: The step S2 comprises: S21, macrophage RAW264.7 cells were incubated with 10 ng / mL lipopolysaccharide LPS, and then activated macrophage membranes were obtained by ultrasonic extraction and centrifugation; S22, incubate normal fibroblasts NIH3T3 with 10 ng / mL TGF-β1, and then extract activated fibroblast membranes by ultrasound and centrifugation; S23. The activated macrophage membrane and the activated fibroblast membrane are mixed by ultrasound at a mass ratio of 1:1, and the membrane fusion is promoted by repeated extrusion through a polycarbonate porous membrane to obtain an activated macrophage / fibroblast hybrid cell membrane.
4. The method for preparing the nanomedicine for synergistically defibrosis and inhibiting pancreatic cancer metastasis according to claim 1, characterized in that: The step S3 comprises: 1 mg / mL small molecule prodrug nanoparticles Cap-tkCA-Cap NPs were mixed with a hybrid membrane of 5 million activated macrophages and 5 million fibroblasts and then sonicated, and then extruded through a polycarbonate porous membrane to obtain the nanodrug Cap-tkCA-Cap@CM.
5. The method for preparing the nanomedicine for synergistically defibrosis and inhibiting pancreatic cancer metastasis according to claim 3 or 4, characterized in that: The pore size of the polycarbonate porous membrane is 100-400 nm.
6. A nanomedicine prepared by the method according to any one of claims 1 to 5 that synergistically resolves fibrosis and inhibits pancreatic cancer metastasis.
Citation Information
Cited By
Tumor cell treatment method based on polypeptide nanotechnology
CN119925635A
Drug-loaded gelatin nanogel, bionic nanogel, preparation method of drug-loaded gelatin nanogel, preparation method of bionic nanogel, combined drug and application of drug-loaded gelatin nanogel and bionic nanogel
CN121868225A
Drug-loaded gelatin nanogel, biomimetic nanogel, preparation method thereof, combined drug and use
CN121868225B
Nanodrug for synergistically removing fibrosis and inhibiting pancreatic cancer metastasis and preparation method therefor
WO2026031838A1
